Zacks Research Analysts Lower Earnings Estimates for Avanos Medical, Inc. (NYSE:AVNS)

Avanos Medical, Inc. (NYSE:AVNS) – Analysts at Zacks Research dropped their Q4 2024 earnings per share estimates for shares of Avanos Medical in a research note issued to investors on Thursday, May 23rd. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.49 per share for the quarter, down from their previous estimate of $0.51. The consensus estimate for Avanos Medical’s current full-year earnings is $1.38 per share. Zacks Research also issued estimates for Avanos Medical’s Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $1.81 EPS, Q1 2026 earnings at $0.49 EPS and FY2026 earnings at $2.27 EPS.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.02). The firm had revenue of $166.10 million during the quarter, compared to the consensus estimate of $162.90 million. Avanos Medical had a negative net margin of 9.15% and a positive return on equity of 4.10%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.27 earnings per share.

Several other research firms also recently issued reports on AVNS. StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 11th. JMP Securities restated a “market perform” rating on shares of Avanos Medical in a research note on Tuesday, May 7th.

Avanos Medical Stock Down 2.5 %

AVNS opened at $19.85 on Friday. The business has a fifty day simple moving average of $19.37 and a 200 day simple moving average of $20.01. Avanos Medical has a 1 year low of $17.24 and a 1 year high of $26.56. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.47 and a current ratio of 2.28.

Insider Activity

In other news, CFO Michael Greiner sold 8,000 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $19.12, for a total value of $152,960.00. Following the completion of the transaction, the chief financial officer now owns 151,495 shares of the company’s stock, valued at $2,896,584.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Avanos Medical

Several hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Avanos Medical by 52.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,627 shares of the company’s stock worth $195,000 after purchasing an additional 3,330 shares during the period. Illinois Municipal Retirement Fund bought a new stake in shares of Avanos Medical in the 3rd quarter valued at about $563,000. Barclays PLC increased its stake in shares of Avanos Medical by 24.4% in the third quarter. Barclays PLC now owns 39,042 shares of the company’s stock valued at $790,000 after buying an additional 7,646 shares during the period. New York State Common Retirement Fund raised its position in shares of Avanos Medical by 36.3% during the third quarter. New York State Common Retirement Fund now owns 38,470 shares of the company’s stock worth $778,000 after acquiring an additional 10,242 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Avanos Medical in the third quarter worth approximately $237,000. Institutional investors and hedge funds own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.